Inhibrx Biosciences, Inc. Quarterly Liabilities and Equity in USD from Q4 2023 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary: Inhibrx Biosciences, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2023 to Q2 2024.
Inhibrx Biosciences, Inc. Liabilities and Equity for the quarter ending June 30, 2024 was $258M.

Liabilities and Equity, Quarterly (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q2 2024	$258M			Jun 30, 2024	10-Q	2024-08-13
Q4 2023	$308M			Dec 31, 2023	10-Q	2024-08-13

* An asterisk sign (*) next to the value indicates that the value is likely invalid.